Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

Women are often underrepresented in clinical trials, leading to uncertainty in subgroup analyses by sex and lower quality data to guide evidence-based therapy.1,2 While many individual trials are inconclusive, patient-level meta-analyses show that women with established cardiovascular disease benefit from statin therapy to the same degree as men.3 However, sex-specific data for non-statin lipid-lowering therapies are sparse.2 A recent statement by the European Society of Atherosclerosis highlighted differences in lipoprotein concentrations through the life course in women versus men, as well as sex differences in the relationships of lipoprotein levels to cardiovascular risk.

Source: Journal of Clinical Lipidology - April 9, 2024 Category: Lipidology Authors: Vera A. Bittner, Gregory G. Schwartz, Deepak L. Bhatt, Terrance Chua, H. Asita De Silva, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Jennifer McGinniss, Robert Pordy, Genevieve Garon, Michel Scemama, Harvey D. White, Ph. Gabriel Tags: Original Research Source Type: research